The U.S. Food and Drug Administration (USFDA) has conducted a GMP surveillance Inspection at Biocon’s API facility (Site 6), located at Visakhapatnam, Andhra Pradesh. The inspection was conducted between November 3 and November 7, 2025. The inspection was concluded with two observations.
Biocon is India’s largest and Asia’s leading Biotechnology Company with a strategic focus on biopharmaceuticals and research services. It is a fully integrated, innovation driven biopharma enterprise offering affordable solutions for chronic diseases to patient's worldwide.
